Safety and efficacy of early anticoagulation drug regimens after WATCHMAN left atrial appendage closure: three-month data from the EWOLUTION prospective, multicentre, monitored international WATCHMAN LAA closure registry

Martin W. Bergmann1*, MD, PhD, FESC; Timothy R. Betts2, MD, MBChB, FRCP; Horst Sievert3, MD, FESC, FACC, FSCAI; Boris Schmidt4, MD; Evgeny Pokushalov5, MD, PhD; Stephan Kische6, MD; Thomas Schmitz7, MD; Felix Meincke8, MD; Kenneth M. Stein9, MD, FACC, FHRS; Lucas V.A. Boersma10, MD, PhD, FESC; Hüseyin Ince11, MD

1. Cardiologicum Hamburg, Hamburg, Germany; 2. Department of Cardiology, John Radcliffe Hospital, Oxford, United Kingdom; 3. Department of Cardiology, CardioVascular Center Frankfurt, Frankfurt am Main, Germany; 4. Cardioangiologisches Centrum Bethanien (

Aims: While LAA closure has recently been incorporated into both European and US guidelines for stroke prevention, uncertainties regarding post-procedural drug therapy so far limit its ad

Sign in to read and download the full article

Login Forgot your password?

No account yet? Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

adjunctive pharmacotherapyatrial fibrillationbleedingleft atrial appendage (laa)laa closurestroke

Interventions for strokeLAA closureTools, devices and techniques

Share on Facebook Share on Twitter Share on Linkedin

Read next article

Bioresorbable vascular scaffold in chronic total occlusions